NCT00504972 2018-05-29
Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies
Weill Medical College of Cornell University
Phase 1 Completed
Clinical Trials
3 trialsNCT00989586 2017-02-06
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
NCT00868478 2010-06-02
The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
Kaplan Medical Center
Phase 1/2 Unknown